Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

Infection and Immunity

Volumn 83, Issue 5, 2015, Pages 2043-2052

  Elsegeiny, Waleed ^a,b   Eddens, Taylor ^a,b   Chen, Kong ^b   Kolls, Jay K ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD20 ANTIBODY; CD20 ANTIGEN; CD4 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5D2; MONOCLONAL ANTIBODY GK1.5; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; RITUXIMAB;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL IMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION SENSITIVITY; LUNG ALVEOLUS CELL; MONOTHERAPY; MOUSE; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAG1-/- MOUSE; T CELL DEPLETION; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG EFFECTS; IMMUNOLOGY; PNEUMOCYSTIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; IMMUNOLOGIC FACTORS; MICE, INBRED C57BL; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; RITUXIMAB;

EID: 84928202521     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.03099-14     Document Type: Article

References (33)

1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. 1994. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
2. Scott SD. 1998. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 6:195-197. http://dx.doi.org/10.1046/j.1523-5394.1998.006003195.x.
3. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, van Lier RA. 2010. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 120:214-222. http://dx.doi.org/10.1172/JCI40231.
4. Deborska-Materkowska D, Kozinska-Przybyl O, Mikaszewska-Sokolewicz M, Durlik M. 2014. Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis- case report. Transplant Proc 46:2908-2911. http://dx.doi.org/10.1016/j.transproceed.2014.09.010.
5. Farkas JD, Clouser RD, Garrison GW. 2014. Pneumocystis pneumonia following rituximab. Chest 145:663-664. http://dx.doi.org/10.1378/chest.13-2539.
6. Martin-Garrido I, Carmona EM, Specks U, Limper AH. 2013. Pneumocystis pneumonia in patients treated with rituximab. Chest 144:258-265. http://dx.doi.org/10.1378/chest.12-0477.
7. Kurokawa T, Kaya H, Yoshida T. 2010. Two cases of Pneumocystis jirovecii pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab. J Clin Exp Hematopathol 50:159-162. http://dx.doi.org/10.3960/jslrt.50.159.
8. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. 1990. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 322:161-165.
9. Stansell JD, Osmond DH, Charlebois E, LaVange L, Wallace JM, Alexander BV, Glassroth J, Kvale PA, Rosen MJ, Reichman LB, Turner JR, Hopewell PC. 1997. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 155:60-66.
10. Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ, Ermak TH. 1990. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 85:1686-1693. http://dx.doi.org/10.1172/JCI114621.
11. Hanano R, Reifenberg K, Kaufmann SH. 1996. Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection. Infect Immun 64:3201-3209.
12. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. 1997. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun 65:5052-5056.
13. Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. 2003. Clearance of Pneumocystis carinii in mice is dependent on B-cells but not on P. carinii-specific antibody. J Immunol 171:1423-1430. http://dx.doi.org/10.4049/jimmunol.171.3.1423.
14. Marcotte H, Levesque D, Delanay K, Bourgeault A, de la Durantaye R, Brochu S, Lavoie MC. 1996. Pneumocystis carinii infection in transgenic B-cell-deficient mice. J Infect Dis 173:1034-1037. http://dx.doi.org/10.1093/infdis/173.4.1034.
15. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. 2006. B-cells are required for generation of protective effector and memory CD4+ cells in response to Pneumocystis lung infection. J Immunol 176:6147-6154. http://dx.doi.org/10.4049/jimmunol.176.10.6147.
16. Canaani J, Amit S, Ben-Ezra J, Cohen Pour M, Sarid N, Lerman H, Perry C, Polliack A, Naparstek E, Herishanu Y. 2013. Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma. J Clin Oncol 31: e178-e180. http://dx.doi.org/10.1200/JCO.2012.43.6188.
17. Zheng M, Shellito JE, Marrero L, Zhong Q, Julian S, Ye P, Wallace V, Schwarzenberger P, Kolls JK. 2001. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest 108:1469-1474. http://dx.doi.org/10.1172/JCI13826.
18. Ricks DM, Chen K, Zheng M, Steele C, Kolls JK. 2013. Dectin immunoadhesins and Pneumocystis pneumonia. Infect Immun 81:3451-3462. http://dx.doi.org/10.1128/IAI.00136-13.
19. Shellito JE, Tate C, Ruan S, Rolls J. 2000. Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii. J Infect Dis 181:2011-2017. http://dx.doi.org/10.1086/315487.
20. Steele C, Marrero L, Swain S, Harmsen AG, Zheng M, Brown GD, Gordon S, Shellito JE, Kolls JK. 2003. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 198:1677-1688. http://dx.doi.org/10.1084/jem.20030932.
21. McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK. 2006. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of Pneumocystis pneumonia. J Immunol 177:6215-6226. http://dx.doi.org/10.4049/jimmunol.177.9.6215.
22. Rostved AA, Sassi M, Kurtzhals JA, Sorensen SS, Rasmussen A, Ross C, Gogineni E, Huber C, Kutty G, Kovacs JA, Helweg-Larsen J. 2013. Outbreak of Pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii. Transplantation 96:834-842. http://dx.doi.org/10.1097/TP.0b013e3182a1618c.
23. Ponce CA, Gallo M, Bustamante R, Vargas SL. 2010. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 50:347-353. http://dx.doi.org/10.1086/649868.
24. Shteinberg M, Shaked-Mishan P, Kinarti A, Abramovitch A, Amital A, Jacobi A, Kolup Feldmann AE, Shiner M, Gershtein V, Weber G, Adir Y. 2014. Asymptomatic carriage of Pneumocystis jirovecii and cytomegalovirus in lungs of immunocompetent patients. Lung 192:875-879. http://dx.doi.org/10.1007/s00408-014-9644-z.
25. Marco H, Smith R, Jones R, Guerry M-J, Catapano F, Burns S, Chaudhry A, Smith K, Jayne D. 2014. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 15:178. http://dx.doi.org/10.1186/1471-2474-15-178.
26. Gigliotti F. 1992. Host species-specific antigenic variation of a mannosylated surface glycoprotein of Pneumocystis carinii. J Infect Dis 165:329-336. http://dx.doi.org/10.1093/infdis/165.2.329.
27. Sunkin SM, Stringer JR. 1996. Translocation of surface antigen genes to a unique telomeric expression site in Pneumocystis carinii. Mol Microbiol 19:283-295. http://dx.doi.org/10.1046/j.1365-2958.1996.375905.x.
28. Sun L, Huang M, Wang J, Xue F, Hong C, Guo Z, Gu J. 2015. Genotyping of Pneumocystis jirovecii isolates from human immunodeficiency virus-negative patients in China. Infect Genet Evol 31C:209-215. http://dx.doi.org/10.1016/j.meegid.2015.01.021.
29. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Jr, Hamill RJ. 2005. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (London, England) 19:399-406. http://dx.doi.org/10.1097/01.aids.0000161769.06158.8a.
30. Lai RP, Nakiwala JK, Meintjes G, Wilkinson RJ. 2013. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 43:1995-2002. http://dx.doi.org/10.1002/eji.201343632.
31. Longley N, Harrison TS, Jarvis JN. 2013. Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis 26:26-34. http://dx.doi.org/10.1097/QCO.0b013e32835c21d1.
32. Antonelli LR, Mahnke Y, Hodge JN, Porter BO, Barber DL, DerSimonian R, Greenwald JH, Roby G, Mican J, Sher A, Roederer M, Sereti I. 2010. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 116:3818-3827. http://dx.doi.org/10.1182/blood-2010-05-285080.
33. Swain SD, Meissner NN, Harmsen AG. 2006. CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in Pneumocystis pneumonia in B-cell-deficient mice. Am J Pathol 168:466-475. http://dx.doi.org/10.2353/ajpath.2006.050724.